Galera Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.galeratx.com
A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03194139
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03164109
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03163173
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03099824
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03096756
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT02508389
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Ohio State University, James Cancer Center, Columbus, Ohio, United States
🇺🇸Thomas-Jefferson University Hospital-Bodine Center for Cancer Treatment, Philadelphia, Pennsylvania, United States
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01921426
- Locations
- 🇺🇸
Summa Health System- Cooper Cancer Center, Akron, Ohio, United States
🇺🇸Lakeland Regional Cancer Center, Lakeland, Florida, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath